X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2023/02/03/2601665/0/en/Patients-with-hidradenitis-suppurativa-experienced-sustained-efficacy-and-symptom-improvement-at-one-year-when-treated-with-Novartis-Cosentyx.html
https://www.fiercepharma.com/pharma/novartis-ties-hq-raid-anticompetition-probe-cosentyx-patent-fight-against-lilly
https://www.globenewswire.com/news-release/2022/09/10/2513541/0/en/Novartis-Cosentyx-shows-clinically-meaningful-symptom-improvements-in-patients-with-hidradenitis-suppurativa-in-pivotal-Phase-III-trials.html
https://www.pharmatimes.com/news/eu_approves_norvatis_cosentyx_for_childhood_arthritis_1450588
https://www.globenewswire.com/news-release/2022/05/20/2447681/0/en/Novartis-Cosentyx-secukinumab-receives-positive-CHMP-opinion-for-expanded-use-in-childhood-arthritic-conditions.html
https://www.fiercebiotech.com/biotech/acelyrin-reels-250m-to-fund-three-late-stage-trials-inflammatory-disease-antibody-licensed
https://www.europeanpharmaceuticalreview.com/news/165277/cosentyxdisplays-a-72-percent-reduced-arthritis-flare-risk/
https://www.clinicaltrialsarena.com/news/novartis-cosentyx-flare-idiopathic-arthritis/
https://www.biospectrumasia.com/analysis/28/19032/key-players-in-psoriasis-offer-strong-support-through-branded-digital-channels-in-australia.html
http://www.pharmafile.com/news/587067/nice-approves-secukinumab-young-people-severe-plaque-psoriasis
Market Place
Share 
